pharma · Relapsing-Remitting Multiple Sclerosis · Spinal Muscular Atrophy
Biogen
Biogen is a pharma organization headquartered in VISAKHAPATNAM, IN. Primary therapeutic focus areas include Relapsing-Remitting Multiple Sclerosis, Spinal Muscular Atrophy, systemic lupus erythematosus, IgA nephropathy,
Company details
- Status
- Public
- HQ
- 225 Binney Street, Cambridge, MA 02142, US
- Employees
- 7,534
- Programs
- 0
- Drugs
- 28
- Patents
- 0
Quick answer
Biogen is a pharma organization headquartered in VISAKHAPATNAM, IN. Primary therapeutic focus areas include Relapsing-Remitting Multiple Sclerosis, Spinal Muscular Atrophy, systemic lupus erythematosus, IgA nephropathy, Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus. NovaPharmaNews links 31 clinical program(s), 5 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (21), phase 1 (4), phase 2 (4).
Company snapshot
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities, to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks
- 9 approved product(s) across US/EU regulatory metadata.
- 31 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for Biogen. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- trial_data
Eisai's Leqembi Sales Forecast: Projecting Blockbuster Status in Alzheimer's
- approval
Biogen's Alzheimer's Data and Leadership Shake-up: Implications for Pharma BD
- approval
Biogen Faces Italian Antitrust Probe: What It Means for the Multiple Sclerosis Market
- approval
Biogen and Eisai expand Leqembi access with subcutaneous maintenance dosing
Recent coverage
Biogen and Eisai expand Leqembi access with subcutaneous maintenance dosing
Biogen and Eisai have expanded LEQEMBI access in the U.S. with subcutaneous maintenance dosing, following FDA approval of the BLA in August 2025. The move could improve convenience, reduce infusion-related burden, and shape investor expectations for Eisai and Biogen stock.
Biogen Faces Italian Antitrust Probe: What It Means for the Multiple Sclerosis Market
Biogen's Italian subsidiary and its US parent are under investigation by the Italian antitrust authority for alleged abuse of a dominant position in the multiple sclerosis market. This probe, stemming from concerns over drug pricing and market practices, could have significant repercussions for Biogen and the broader MS therapeutic area.
Biogen's Alzheimer's Data and Leadership Shake-up: Implications for Pharma BD
Biogen faces scrutiny following recent Alzheimer's data releases and executive departures. This analysis explores the implications for pharmaceutical business development and investment strategies.
Eisai's Leqembi Sales Forecast: Projecting Blockbuster Status in Alzheimer's
Eisai projects significant growth for its Alzheimer's treatment, Leqembi, with sales forecasts indicating a strong path toward blockbuster status. This analysis explores the drivers behind this projection and its strategic implications for the pharmaceutical industry.
Top assets
Lead pipeline drugs
- approved
- Marketed / approved
- approved
- approved
Momentum signals
Momentum
Proprietary activity score for Biogen.
3 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitive landscape
Recent activity
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Biogen?
-
Is Biogen publicly traded?
-
What drugs does Biogen develop or market?
-
What are the latest developments for Biogen?
-
What therapeutic areas does Biogen focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.